Researchers at the Cleveland Clinic warn that the use of an investigational diabetes drug called muraglitazar (Pargluva, Bristol-Myers Squibb/Merck) may double the risk of death, heart attack, and stroke. They say that the FDA should not approve the drug until its cardiovascular safety can be proven in a “dedicated” trial of cardiovascular events. The FDA had issued an approvable letter.
The drug is a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) activator. It targets both glycosylated hemoglobin (HbA1c) and serum lipids.